» Articles » PMID: 25262109

Enhanced Vascular Endothelial Growth Factor Signaling in Islets Contributes to β Cell Injury and Consequential Diabetes in Spontaneously Diabetic Torii Rats

Overview
Specialty Endocrinology
Date 2014 Sep 29
PMID 25262109
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: Spontaneously diabetic Torii (SDT) rats exhibit vascular abnormalities in pancreatic islets as the initial changes at pre-diabetes stage (8 weeks old), which is followed by β cell deterioration. In the present study, we investigated pathophysiological interactions between β cells and intra-islet microvasculature of SDT rats at pre- and peri-onset of diabetes.

Methods: SDT rats were treated with Habu snake venom (HSV) to assess its hemorrhagic effects in glomeruli and pancreatic islets. SDT rats were treated with streptozotocin (STZ) to assess acute β cell fragility toward cytotoxic insult and the late-stage consequence of β cell ablation in neighboring structures. The receptor tyrosine kinase inhibitor sunitinib was administered to SDT rats to examine its therapeutic effect.

Results: HSV administration at 5 weeks old induced severe hemorrhage in and around islets in SDT rats. By contrast, precedent β cell depletion using STZ ameliorated hemorrhage, inflammation, and fibrosis around the islets at 13 weeks old, which is normally seen in SDT rats of this age. Blockade of vascular endothelial growth factor (VEGF)-like activity attenuated HSV-induced hemorrhage in SDT islets. VEGF release from SDT islets was increased at 13 weeks old but not at 5 weeks old, while interleukin-1β release was increased as early as 5 weeks old. Sunitinib treatment started at 5 weeks of age inhibited the onset of intra-islet hemorrhage, β cell loss, and hyperglycemia in SDT rats.

Conclusions: Enhanced VEGF signaling in islets contributes to β cell injury, microvascular failure, and consequential diabetes in SDT rats.

Citing Articles

Long-term effects of gestational diabetes mellitus on the pancreas of female mouse offspring.

Munoz-Islas E, Santiago-SanMartin E, Mendoza-Sanchez E, Torres-Rodriguez H, Ramirez-Quintanilla L, Peters C World J Diabetes. 2024; 15(4):758-768.

PMID: 38680692 PMC: 11045410. DOI: 10.4239/wjd.v15.i4.758.


Future treatment of Diabetes - Tyrosine Kinase inhibitors.

Kumar S A, Patel S, Patel S, Parikh P J Diabetes Metab Disord. 2023; 22(1):61-71.

PMID: 37255821 PMC: 10225458. DOI: 10.1007/s40200-022-01164-3.


Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications.

Zhong Q, Xiao X, Qiu Y, Xu Z, Chen C, Chong B MedComm (2020). 2023; 4(3):e261.

PMID: 37143582 PMC: 10152985. DOI: 10.1002/mco2.261.


Tyrosine Kinase Targeting: A Potential Therapeutic Strategy for Diabetes.

Althubiti M Saudi J Med Med Sci. 2022; 10(3):183-191.

PMID: 36247049 PMC: 9555044. DOI: 10.4103/sjmms.sjmms_492_21.


Immune disorders and sex differences in spontaneously diabetic Torii rats, type 2 diabetic model.

Kobayashi K, Sasase T, Maekawa T, Shinozaki Y, Sano R, Yamada T Physiol Res. 2022; 71(1):113-123.

PMID: 35043654 PMC: 8997669. DOI: 10.33549/physiolres.934825.